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Familial hypercholesterolemia (FH) is the most common genetic dis-
order causing premature cardiovascular disease and death. Heterozy-
gous FH conservatively affects approximately 1:500 Canadians, and
the more serious homozygous form affects approximately
1:1,000,000 Canadians, although these numbers might be under-
estimated. Of approximately 83,500 Canadians estimated to have FH,
most are undiagnosed, which represents a simultaneous public health
deﬁcit and opportunity, because early treatment of heterozygous
FH can normalize life expectancy. Diagnostic algorithms for FH
Familial hypercholesterolemia (FH) is an autosomal codominant
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L’hypercholesterolemie familiale (HF) qui est la maladie genetique la
plus frequente entraîne de manière precoce la maladie cardiovascu-
laire et la mort. Bien que ces chiffres puissent être sous-estimes, la
forme heterozygote de l’HF touche environ 1 Canadien sur 500, alors
que la forme homozygote, qui s’avère être la forme la plus serieuse,
touche environ 1 Canadien sur 1 000 000. On estime que parmi les
quelque 83 500 Canadiens souffrant d’HF la plupart ne sont pas
diagnostiques, ce qui represente simultanement un deﬁcit et une
opportunite pour la sante publique, puisque le traitement precoce dedensity lipoprotein (LDL) cholesterol (LDL-C), increased car-
disorder leading to premature coronary heart disease and cardiac
death. FH is often unrecognized until the inaugural cardiovas-diovascular riskdby up to 20-folddand early onsetcardiovascular disease.1-3 FH is the most common monogenic
cular event. Early diagnosis and treatment of FH can normalizeformulate disease-speciﬁc recommendations. These recommendations are
aimed to provide a reasonable and practical approach to care for specialists and
allied health professionals obliged with the duty of bestowing optimal care to
patients and families, and can be subject to change as scientiﬁc knowledge and
technology advance and as practice patterns evolve. The statement is not
intended to be a substitute for physicians using their individual judgment in
managing clinical care in consultation with the patient, with appropriate re-
gard to all the individual circumstances of the patient, diagnostic and treat-
ment options available and available resources. Adherence to these
recommendations will not necessarily produce successful outcomes in every
case.
This is an open access article under the CC BY-NC-ND license (http://
RECOMMENDATION
1. We suggest implementation of standard processes of
care for the identiﬁcation and treatment of subjects
with FH (Conditional Recommendation, Moderate-
Quality Evidence).
incorporate increased plasma low-density lipoprotein cholesterol,
pathognomonic clinical features, and family history of early cardio-
vascular disease and hyperlipidemia. DNA-based detection of causa-
tive mutations in FH-related genes can help with diagnosis. Maximizing
diagnosis and treatment of FH in Canada will involve a multipronged
approach, including: (1) increasing awareness of FH among health
care providers and patients; (2) creating a national registry for FH in-
dividuals; (3) setting standards for screening, including cascade
screening in affected families; (4) ensuring availability of standard-of-
care therapies, in particular optimization of plasma low-density
lipoprotein cholesterol levels and timely access to future validated
therapies; (5) promoting patient-based support and advocacy groups;
and (6) forming alliances with international colleagues, resources, and
initiatives that focus on FH. This document aims to raise awareness of
FH nationally, and to mobilize knowledge translation, patient support,
and availability of treatment and health care resources for this
underrecognized, but important medical condition.
la forme heterozygote de l’HF peut normaliser l’esperance de vie. Les
algorithmes diagnostiques de l’HF incorporent l’augmentation de la
concentration plasmatique du cholesterol à lipoproteines de basse
densite, les signes cliniques pathognomoniques et les antecedents
familiaux de maladie cardiovasculaire precoce et d’hyperlipidemie.
L’analyse de l’ADN pour la detection des mutations causales dans les
gènes lies à l’HF peut faciliter le diagnostic. La maximisation du
diagnostic et du traitement de l’HF au Canada impliquera une appro-
che à volets multiples, y compris : 1) accroître la sensibilisation des
prestataires de soins de sante et des patients à l’HF; 2) creer un reg-
istre national d’individus souffrant de l’HF; 3) ﬁxer des normes de
depistage, y compris le depistage en cascade auprès des familles
touchees; 4) assurer la disponibilite des traitements correspondant
aux normes de soins, en particulier l’optimisation des concentrations
plasmatiques de cholesterol à lipoproteines de basse densite et l’ac-
cès en temps opportun aux traitements valides futurs; 5) promouvoir
les groupes de soutien et de defense des droits des patients; 6) con-
clure des alliances internationales avec les collègues, les ressources et
les initiatives qui se concentrent sur l’HF. Ce document a pour objectif
d’accroître la sensibilisation de l’HF sur le plan national et de mobiliser
les connaissances, le soutien au patient et la disponibilite des traite-
ments et des ressources en soins de sante concernant cette maladie
meconnue, mais importante.
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Volume 30 2014life expectancy. If left untreated, men with FH develop cardio-
vascular disease in the third to fourth decade of life and women
10 years later on average. The prevalence of heterozygous FH
(HeFH) had been conservatively estimated at 1:500, based on a
survey of familial lipoprotein disorders in myocardial infarction
survivors.4 Recent molecular studies indicate that 3.4% of pa-
tients with early myocardial infarction have FH mutations.5
Increased rates of FH are observed in populations in which
founder effects are present.1 The prevalence of HeFH in French-
Canadians is estimated at approximately 1:270.6 Thus, assuming
that the prevalence of HeFH in the rest of Canada is 1:500, and
that populations of Quebec and the rest of Canada are 8 and 27
million, respectively, the number of FH subjects in Canada is
approximately 83,500, although this likely underestimates the
true number, because recent population surveys using direct
molecular screening in Europeans diagnosed approximately
1:250 individuals with HeFH.1,3,7 Unfortunately, most FH
patients are unrecognized, because of factors including incon-
sistent screening practices and general unawareness regarding
diagnosis. National programs that include a patient registry and
targeted cascade screening for FH have proven to be cost-
effective and to improve outcomes in several European coun-
tries. The aim of this Position Statement is to raise awareness and
stimulate discussion toward development of national guidelines
for the diagnosis and treatment of FH in Canada.
Choice of Outcomes and Appraisal of the
Evidence
The most relevant outcomes in the diagnosis and care of
patients with FH are: (1) biochemical, speciﬁcally attaining
optimal LDL-C levels; (2) clinical, primarily reducing car-
diovascular events; and (3) societal, including processes of
care. Another potential outcome is sequential imaging of
atherosclerosis burden as a surrogate marker for the treatment
effectiveness (see the section on Secondary Testing and Im-
aging in FH). No randomized cardiovascular end point trialsexist to prove that lowering of LDL-C should be the primary
treatment target in FH patients, however overwhelming evi-
dence from the general population indicates that reducing
LDL-C is effective.8 Moreover, the totality of evidence
reviewed strongly suggests that early diagnosis and institution
of multidimensional risk factor modiﬁcation in FH patients,
including lifestyle modiﬁcation and appropriate use of phar-
macotherapy is cost-effective and life-saving.Processes of Care As an Outcome
Underestimation of FH prevalence and insufﬁcient aware-
ness of favourable cost-beneﬁt of interventions, make the
implementation of processes of care at the societal level a key
outcome. Such primary processes include: (1) prompt recog-
nition of patients at high risk of having FH (eg, adults with
LDL-C > 5.0 mmol/L); (2) implementation of strict lifestyle
changes in patients with probable or deﬁnite FH, including
smoking cessation, prudent diet, weight management, avoid-
ance of sedentary lifestyle, and control of other cardiovascular
risk factors; (3) referral of probable and deﬁnite cases of FH for
specialist care; (4) cascade screening of probands and relatives to
identify additional cases; (5) construction of a national FH
registry to collect data on FH incidence and prevalence and to
disseminate educational material to health care providers, pa-
tients, and the general public; and (6) education of primary care
physicians, and specialists in internal medicine, pediatrics,
cardiology, endocrinology, and obstetrics and gynecology on
the basics of diagnosis and treatment of FH.
Values and Preferences. Stakeholders in health care
management should support regional centres of expertise
in the detection of FH, cascade screening, and molecular
diagnosis.
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Early diagnosis of FH enables early initiation of preventive
measures to reduce cardiovascular disease risk.9 In Canada,
most HeFH patients are diagnosed using clinical and
biochemical features,10 including: (1) very high LDL-C
(typically > 5.0 mmol/L); (2) typical physical ﬁndings (stig-
mata) such as tendon xanthomata, xanthelasma, and arcus
corneae (Fig. 1); (3) personal history of early cardiovascular
disease; and (4) family history of early cardiovascular disease or
of marked hyperlipidemia, often requiring treatment.
Secondary or nongenetic causes of increased LDL-C1,10
must ﬁrst be ruled out (Table 1). The most commonly used
diagnostic algorithms for HeFH are the United Kingdom
Simon Broome Registry11 and the Dutch Lipid Clinic
Network criteria12 (Table 2). The less widely used USMedPed
criteria focuses on LDL-C levels, without regard to clinical
features.13 The Simon Broome Registry and Dutch Lipid
Clinic Network criteria incorporate weighted combinations of
the aforementioned factors,11,12 and produce scores that lead to
classiﬁcation of either “deﬁnite” or “probable” FH, with a third
category of “possible FH” in the Dutch Lipid Clinic Network
system. Detection of a pathogenic DNA mutation in an FH-
related gene essentially leads to a diagnosis of “deﬁnite
FH”.11,12 Head-to-head comparisons suggest that the Simon
Broome Registry and Dutch Lipid Clinic Network criteria
perform comparably well in diagnosing HeFH.14 DNA
sequence analysis of FH-associated genes can help in speciﬁc
instances (see Supplemental material sub-section “DNA testing
for FH” and Fig. 2). There are several reasons to consider
development of Canadian-speciﬁc diagnostic criteria for FH
(see Supplemental material sub-section “Need for new Cana-
dian-speciﬁc diagnostic criteria for HeFH”, and Fig. 3).Figure 1. Physical ﬁndings (stigmata) in FH. (A) Bilateral xanthelasma
on eyelids. (B) Bilateral arcus corneae, which are pathognomonic
when detected by the ﬁfth decade of life, but are nonspeciﬁc to FH by
the eighth decade of life. (C) Arrows indicate xanthoma with the
extensor tendon of the hand. (D) Arrows indicate xanthomas within
the Achilles tendons. FH, familial hypercholesterolemia.
RECOMMENDATION
2. We suggest that the diagnosis of FH should rely on the
Simon Broome Registry or Dutch Lipid Clinic
Network criteria (Conditional Recommendation,
Moderate-Quality Evidence).
Values and Preferences. Because there is no “gold
standard” to diagnose FH, further clariﬁcation of speciﬁc
criteria to facilitate diagnosis is requireddespecially to
increase diagnostic sensitivity in the primary care setting.Screening for FH in Adults
Early detection of affected individuals is the cornerstone of
cardiovascular disease prevention. Furthermore, FH is among
the few genetic disorders that meets all conditions for large-
scale screening programs.15 Universal screening for dyslipi-
demia is already recommended for Canadian men 40 years of
age and older, for women 50 years of age and older, or those
who are postmenopausal, and for subjects at risk of cardio-
vascular disease; some cases of FH will be found this way.16To maximize identiﬁcation of previously undiagnosed adult
FH subjects, 2 complementary strategies are proposed: (1)
targeted screening to identify FH index cases (probands)
among hypercholesterolemic adults with at least 1 feature such
as personal or family history of clinical stigmata, personal or
familial history of premature cardiovascular disease, or family
history of signiﬁcant hypercholesterolemia; and (2) cascade
screeningdor systematic family tracingdof ﬁrst-, second-,
and eventually third-degree relatives of probands to detect
Table 1. Secondary causes of severe increased low-density lipoprotein
cholesterol
 Obstructive liver disease
 Hypothyroidism
 Nephrotic syndrome
 Anorexia
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case.11 Identiﬁcation of index cases requires a fasting lipid
proﬁle performed while the subject is free of intercurrent ill-
nesses. Although cascade screening is largely based on LDL-C
levels, screened subjects with “possible” or “probable” FH can
be considered for genetic testing to conﬁrm the diagnosis (see
Supplemental material sub-section “DNA testing for FH”).
Cascade screening, starting with LDL-C measurement,
after ascertaining an index patient, can effectively identify
related affected individuals who can be treated. Because
HeFH shows autosomal dominant transmission, 50%, 25%,Table 2. Criteria for FH*
A. Simon Broome Registry
Criteria
1. A plasma measurement of either:
Total cholesterol > 7.5 mmol/L (adult patient) or > 6.7 mmol/L (child
aged < 16 years)
Low-density lipoprotein cholesterol > 4.9 mmol/L (adult patient) or
> 4.0 mmol/L (child aged < 16 years)
2. Tendon xanthomas in the patient or any of the patient’s ﬁrst- or second-
degree relatives
3. DNA-based evidence in the patient of mutation in LDLR or other FH-
related gene
4. Family history of myocardial infarction before the age of:
50 Years, in any ﬁrst- or second-degree relative
60 Years, in any ﬁrst-degree relative
5. Family history of plasma total cholesterol > 7.5 mmol/L in any ﬁrst- or
second-degree relative
B. Dutch Lipid Clinic Network
Points Criteria Diagnosis
1 First-degree relative with premature
cardiovascular disease or LDL-C
> 95th percentile, or personal
history of premature peripheral or
cerebrovascular disease, or LDL-C
between 4.01 and 4.89 mmol/L
(155 and 189 mg/dL)
Deﬁnite FH ( 8 points)
2 First-degree relative with tendinous
xanthoma or corneal arcus, or First-
degree relative child (< 18 years)
with LDL-C > 95th percentile, or
personal history of coronary artery
disease
Probable FH (6-7 points)
3 LDL-C between 4.91 and 6.44 mmol/L
(190 and 249 mg/dL)
4 Presence of corneal arcus in patient
younger than 45 years of age
5 LDL-C between 6.46 and 8.51 mmol/L
(250 and 329 mg/dL)
Possible FH (3-5 points)
6 Presence of a tendon xanthoma
8 LDL-C > 8.53 mmol/L (330 mg/dL),
or functional mutation in the LDLR
gene
FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein
cholesterol; LDLR, gene encoding the LDL receptor.
* Criteria required for diagnosis of: deﬁnite HeFH, A þ B or C; and
probable HeFH, A þ D or A þ E.and 12.5% of ﬁrst-, second-, and third-degree relatives
screened, respectively, will be affected.11 We suggest that: (1)
Canadian primary care providers should be sensitized to the
diagnosis of FH and offered tools to effectively identify index
cases; (2) national, provincial, and local protocols should be
developed for screening of adults and children with FH; (3)
community laboratories could alert providers about abnormal
LDL-C (eg,  5.0 mmol/L); (4) opportunistic screening
should be performed systematically around the time of a
cardiovascular disease event; (5) Canadian-speciﬁc cascade
screening should be maximally cost-effective, systematic, and
centrally coordinated; (6) national, provincial, and local reg-
istries of FH subjects can support cascade screening; (7) ge-
netic testing should be performed only in specialized,
accredited laboratories; (8) counselling before and after testing
should be available; and (9) local ethics boards should review
the sensitive issue of contacting relatives in the course of
cascade screening.RECOMMENDATION
3. We recommend strategic use of targeted and cascade
screening for timely recognition and treatment of new
adult cases of FH (Strong Recommendation, Low-
Quality Evidence).
Values and Preferences. Cascade screening, starting
with LDL-C measurement, can be considered after the
identiﬁcation of an index patient. DNA testing should be
reserved for cases of diagnostic uncertainty, for example,
when accurate family history is unavailable, when lipid
levels are borderline, when screened family members have
“possible” or “probable” FH, and in cases in which
management will be altered by the results of such testing.Screening for FH in Children
Except for individuals with rare homozygous FH (HoFH),
children with FH have no physical ﬁndings or overt cardio-
vascular disease; hence, detection can only be accomplished
using lipid screening. However, there remain important evi-
dence gaps regarding the beneﬁts, harms, and costs of child-
hood lipid screening.17-19 Also, appropriate management is
limited by lack of resources and time within a busy clinical
practice.20 There will likely never be direct evidence that lipid
screening in childhood reduces cardiovascular disease risk in
adulthood, despite a compelling chain of observational evi-
dence. Atherosclerosis does not progress uniformly across the
lifespan, and is likely preventable and reversible during
childhood. Optimizing risk factors during adolescence was
associated with reduced odds of cardiometabolic risk factors
and early atherosclerosis on carotid ultrasound 21 years
later.21 Trials of statin therapy in children and adolescents
with FH have shown normalized endothelial function,22 and
regression of carotid intima-media thickness,23 which is
effective when initiated at younger ages.24
The case for screening children to detect FH and initiate
treatment is reasonably strong.25,26 As with adults, screening for
FH in children can be accomplished using universal, targeted, or
cardiovascular risk, and should not be used for risk
assessment.
6. For primary prevention in adult FH patients, beginning
at 18 years of age, we recommend a > 50% reduction
of LDL-C from baseline. For secondary prevention, we
recommend striving toward a target LDL-C < 2.0
mmol/L (Strong Recommendation, Low-Quality
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complete case ascertainment. Although cascade screening ap-
pears cost-effective, there are many uncertainties in the
modelling. Because there are even more uncertainties in
modelling its cost-effectiveness, we cannot recommend uni-
versal screening in children. Advice for pediatric screening for
FH from other bodies is discussed in the Supplemental material
section “ADDITIONAL POINTS ON SCREENING”.RECOMMENDATION
4. We suggest targeted screening in children and adolescents
with such cardiovascular risk factors as a positive family
history of dyslipidemia or cardiovascular disease, obesity,
smoking, hypertension, or type 2 diabetes (Conditional
Recommendation, Low-Quality Evidence).
Values and Preferences. Screening the plasma lipid
proﬁle in children with a positive family history, and with
poor lifestyle or cardiovascular risk factors might help
motivate the adoption of preventive strategies.
Evidence).
Values and Preferences. LDL-C is a strong surrogate
for end points such as cardiovascular death, myocardial
infarction, and the need for arterial revascularization.
RECOMMENDATION
7. We suggest that a healthy lifestyle including smoking
cessation, prudent diet, caloric intake to maintain ideal
body weight, daily exercise, and stress reduction be
recommended for FH patients (Conditional Recom-
mendation, Low-Quality Evidence).
Values and Preferences. Randomized trials of lifestyle
modiﬁcation in FH subjects are unlikely to be performed.
However, nonlipid cardiovascular disease risk factors
amplify the already high risk in FH patients and should be
managed.Management of FH in Adults
Overall goals of treatment
Although no randomized trials exist to prove that lowering
LDL-C is the primary treatment target in FH patients,
overwhelming evidence from the general population shows
the effectiveness of reducing LDL-C: a 1 mmol/L reduction
reduces major cardiovascular disease events by approximately
20% after 5 years.8 Nonetheless, coronary heart disease risk is
increased by up to 20-fold in untreated FH patients,1 and
cardiovascular disease events are dramatically reduced in
observational studies of statin-treated FH patients.9,11
Extrapolating from the general population in the context of
the high cardiovascular disease risk level in adult FH hetero-
zygotes, it is reasonable to recommend > 50% reduction from
baseline LDL-C as a minimal target for primary prevention.16
If cardiovascular disease is present, the LDL-C target to be
strived for is < 2.0 mmol/L, although patients with severe
HeFH or HoFH will likely not reach this target without more
aggressive and complex therapy.RECOMMENDATION
5. Conventional cardiovascular risk calculators that assess
short-term risk are inaccurate in FH patients. We
recommend considering all adults with FH as being at
“high risk” as a result of lifelong exposure of arteries to
high LDL-C (Strong Recommendation, Moderate-
Quality Evidence).
Values and Preferences. Because FH patients are often
young, with few other risk factors, risk calculators such as
Framingham, Systematic Coronary Risk Evaluation
(SCORE), and others will underestimate their lifetimeLifestyle factors
In addition to increased LDL-C levels, FH patients are
also vulnerable to other risk factors. Thus, FH patients and
families would beneﬁt from lifestyle management education,
including advice regarding diet, exercise, weight control,
blood pressure control, diabetes control, and smoking
cessation.27,28 Advice to children and young adults to
refrain from starting smoking is especially important.
Structured smoking cessation programs should be offered to
smokers with FH.Pharmaceutical therapies
Statins are the drug class of choice for HeFH, although
clinical end point evidence for speciﬁc levels of absolute or
relative reductions in plasma LDL-C is lacking. Following
from the Canadian Cardiovascular Society guideline rec-
ommendations for adults with dyslipidemia, a reasonable
therapeutic goal for primary prevention in adults with HeFH
is to achieve a > 50% reduction in LDL-C levels,16 a goal
that in many cases is achievable with high-dose statins alone.
When LDL-C still requires reduction, addition of adjunctive
agents is recommended on an individualized basis. In HeFH
patients with established atherosclerotic cardiovascular dis-
ease, the Canadian Cardiovascular Society guideline recom-
mended a goal of LDL-C < 2.0 mmol/L should be at the
top-of-mind, but might not be feasible with currently
available drugs.1
Figure 2. Genetics of FH. (A) Familial inheritance of heterozygous FH (H
respectively. Up to 1:250 matings in Canada involve an HeFH subject and a n
individuals are discussed in “Diagnosis of FH”, Tables 2, and Figure 1. Geno
the HeFH phenotype are shown below each pedigree symbol. Fifty percen
expressed early in life. Because 50%, 25%, and 12.5% of ﬁrst-, second-, an
systematic biochemical cascade screening of family members is considered
genes causing FH. Chromosomal location of the main genes causing dom
receptor (approximately 95% of all causative mutations), APOB encoding ap
proprotein convertase subtilisin kexin 9 (approximately 1% of all mutation
apolipoprotein B; Chr, chromosome; FH, familial hypercholesterolemia; LDL
gene encoding pro-protein convertase subtilisin/kexin type 9.
RECOMMENDATION
8. We recommend that statins should be ﬁrst-line therapy
in FH patients, with the aim of lowering LDL-C by
> 50%. In patients with atherosclerosis, maximally
tolerated doses of statins with or without ezetimibe or
bile acid sequestrants (cholestyramine, colestipol, or
colesevelam) might further decrease LDL-C (Strong
Recommendation, Low-Quality Evidence).
Values and Preferences. Statins have modiﬁed the
natural course of FH. When treated early in life, event-free
survival is essentially normalized in HeFH patients.
1476 Canadian Journal of Cardiology
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Although statins are safe and easy to use, compliance can
be an issue in up to 10% of patients because of side effects.
Statin-related adverse effects have been extensively reviewed:
muscle-related symptoms and early diabetes onset in diabetes-
prone individuals are most consistent, and evidence of effects
on liver function and cognitive function is much weaker.29,30
A large meta-analysis found no difference between statins and
placebo with respect to side effect-related discontinuations,
myalgia, or the incidence of cancer, and there were differences
among individual statins regarding creatine kinase and liver
function abnormalities.31 Additionally, statins appear to be
associated with a small risk of new-onset type 2 diabetes.30eFH). Squares and circles represent male and female individuals,
ormolipidemic individual. Clinical and biochemical features of affected
typic inheritance of FH-causing mutations and their cosegregation with
t of children of such a mating will have HeFH, which is usually fully
d third-degree relatives of an affected individual will also have HeFH,
by many to be a cost-effective approach to ﬁnding new cases. (B) Main
inant HeFH and their chromosomal location: LDLR encoding the LDL
olipoprotein B (approximately 3% of all mutations), PCSK9 encoding
s), and some very rare genes are not shown. APOB, gene encoding
, low-density lipoprotein; LDLR, gene encoding LDL receptor; PCSK9,
Figure 3. Diagnostic and treatment ﬂow when familial hypercholesterolemia (FH) is suspected. APOB, gene encoding apolipoprotein B; C,
cholesterol; LDL, low-density lipoprotein; LDLR, gene encoding LDL receptor; PCSK9, gene encoding pro-protein convertase subtilisin/kexin type 9.
RECOMMENDATION
9. We suggest that all children with a presumptive diag-
nosis of FH ﬁrst undergo at least 12 months of lifestyle
changes, including diet, exercise, and a tobacco-free
environment (Conditional Recommendation, Low-
Quality Evidence).
Values and Preferences. Lifestyle remains the corner-
stone of cardiovascular disease prevention in children and
adolescents with HeFH.
Genest et al. 1477
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were related to presence of metabolic risk factors for new-
onset diabetes, such as obesity, impaired fasting glucose,
hypertriglyceridemia, and hypertension.32 Moreover, the car-
diovascular risk reduction beneﬁt of statins far outweigh the
risk of new-onset diabetes.
Concerns are often ampliﬁed when long-term therapy is
considered for young and prepubertal patients with FH.
Safety evidence speciﬁc to FH patients is not plentiful, but
several meta-analyses show statins are generally very well
tolerated without signiﬁcant effects on growth or
maturation.33-35 Although further evidence would be desir-
able, the current evidence base suggests that statins can be as
safely used in the FH population as in the general population,
but with care in special circumstances, including treatment of
children younger than 8 years of age, and avoidance of use in
women intending to conceive or who are pregnant or breast-
feeding.36
Emerging therapies
Because of the importance of LDL-C as a cardiovascular
disease risk factor, and because FH is the ultimate human
model of extreme increased LDL-C level that increases car-
diovascular disease risk, new classes of drugs to decrease LDL-C
level have been or are being evaluated in FH. Discussed in
detail in the Supplemental material section “EMERGING
THERAPIES IN FH”, these include: (1) oral microsomal
triglyceride transfer protein inhibitors, of which lomitapidewas recently approved in Canada for the restricted indication
of treatment of HoFH37; (2) subcutaneously administered
apolipoprotein B antisense strategies, of which mipomersen
was recently approved in the United States but not Canada38;
(3) orally administered cholesterol ester transfer protein in-
hibitors39; and (4) subcutaneously administered proprotein
convertase subtilisin/kexin type 9 inhibitors.40
Management of FH in Children
Because atherosclerosis in FH starts early in life,41,42 un-
treated children with FH will develop endothelial dysfunction,
premature plaques, and early coronary heart disease.43-46
Levels of LDL-C in FH children, even at birth, were
increased 2- to 3-fold above the normal range. Counselling on
lifestyle modiﬁcation remains the essential starting point in
the care of children and adolescents with FH.
1478 Canadian Journal of Cardiology
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Clinical studies support the efﬁcacy of statin therapy dur-
ing childhood.35 A meta-analysis of clinical trials of statins in
children showed an average LDL-C reduction of 30% (95%
conﬁdence interval, 36% to 24%), with no increased risk
of adverse events, including no increase of hepatic trans-
aminase, a statistically signiﬁcant change in height (0.33 cm;
95% conﬁdence interval, 0.03-0.63 cm) favouring the treat-
ment group, but no effect on pubertal development.35 Similar
data were reported for a longer follow-up period.24 In children
with HeFH, ezetimibe monotherapy was well tolerated and
signiﬁcantly reduced LDL-C.47 Lipoprotein apheresis should
be pursued in children with HoFH, managed at a lipid
specialist centre.48 Initiation of statin therapy, after  12
months of lifestyle changes as discussed herein, is now rec-
ommended at ages 8-10, when FH is believed to be “deﬁ-
nite.”1,49 The LDL-C target in children is < 3.5 mmol/L, but
the presence of additional risk factors or high-risk conditions
might decrease this target to < 2.5 mmol/L or could prompt
initiation of statin therapy at an age younger than 10 years.RECOMMENDATION
10. If drug treatment is believed to be necessary, assessed
on an individual basis, statins are ﬁrst-line therapy,
with ezetimibe and bile acid binding resins considered
as next-line therapies. Niacin is no longer recom-
mended (Conditional Recommendation, Low-
Quality Evidence).
Values and Preferences. A healthy lifestyle is the
therapeutic cornerstone for all children with HeFH, and
initiation of statins on an individualized basis as ﬁrst-line
pharmacological agents depends on additional variables,
such as a high burden of cardiovascular disease risk factors
and the absolute degree of the increase in LDL-C level.
RECOMMENDATION
11. HoFH patients older than 7 years of age and > 15 kg
in weight should be referred to a specialized centre
and considered for extracorporeal plasma exchange or
LDL apheresis and emerging therapies (Conditional
Recommendation, Low-Quality Evidence).
Values and Preferences. Clinical observation has
shown that with apheresis, life expectancy of HoFH patients
has more than doubled in the past 3 decades; this must be
made available in specialized centres across Canada.Secondary Testing and Imaging in FH
Because the lifetime cardiovascular disease risk ranges from
exceptionally high in HoFH to high in HeFH patients, there
is no risk reﬁnement or reclassiﬁcation based on imaging,
because all patients warrant therapy. Several speciﬁc situations
might, however, warrant imaging. Methods to assess symp-
tomatic FH patients should be relevant to the nature of the
symptoms (eg, carotid duplex scanning for assessment of
transient ischemic attacks or exercise testing for evaluation of
chest pain, etc). Assessment of the aortic valve and root using
echocardiography is warranted in patients with HoFH and
perhaps also in those with severe HeFH and concomitant
increased level of Lipoprotein(a) [Lp(a)], which is associated
with aortic valve disease.50-53 Detection of premature
atherosclerosis might be warranted in a patient suspected of
having FH and without family history of cardiovascular dis-
ease.54 Additionally, among individuals who meet “possible
FH” criteria using the Simon Broome Registry or Dutch Lipid
Clinic Network algorithms, detection of increased atheroma
using carotid ultrasound or coronary artery calcium scoring
could increase the chance of ﬁnding a discrete monogenic
cause.55 Stress testing, including stress imaging studies, might
be warranted to rule out silent ischemia in patients whoengage in rigorous exercise.56 Finally, suspicion of hepatic
steatosis as a cause of increased levels of transaminases might
require hepatic ultrasound evaluation.29,30 Vascular imaging is
not recommended to monitor vascular effects of lipid-
lowering therapy even though diverse imaging methods have
been used in mechanistic, surrogate end point trials. The
presence of severe vascular disease in an asymptomatic patient
might prompt more aggressive intervention.Homozygous FH: Identiﬁcation and Treatment
Depending on the population and deﬁnition used, the
prevalence of HoFH ranges from 1 in 250,000 to 1 in
1,000,000 individuals globally, and is increased in founder
populations, such as French-Canadians.6 Diagnostic
criteria are typically based on family history, which include
HeFH in both parents, presence of cutaneous and tendi-
nous manifestations at ages younger than 10 years, severe
increased level of LDL-C (ie, untreated LDL-C > 12-13
mmol/L) and molecular diagnosis.6,57 HoFH patients are at
extremely high risk of cardiovascular disease and should be
evaluated at younger than 2 years of age for optimal pre-
vention.57,68 HoFH patients should be referred to a lipid
specialist centre for cholesterol-lowering therapies,
including extracorporeal LDL removal, which has demon-
strated beneﬁcial effects on aortic and coronary athero-
sclerosis in HoFH59-63 and possibly for trials with new
therapies (see Supplemental material section “EMERGING
THERAPIES IN FH”). Apheresis is recommended in
adults with HoFH with refractory LDL-C > 8.5 mmol/L
and in children (> 15 kg in weight or older than 7 years of
age) with refractory LDL-C > 5.0 mmol/L on maximally
tolerated medical therapy.59-64 Lipid-lowering therapy is
associated with delayed cardiovascular disease events and
prolonged survival, and low-fat diet and optimization of
other risk factors have less effect on the disease course.57,58
Calciﬁc valvular and supravalvular aortic stenoses are
almost universal and frequently require aortic valve
replacement.65 Patients with HoFH who require intensive
LDL-C-lowering therapy with apheresis are generally
monitored every 1-2 years to determine progression of ca-
rotid atherosclerosis (carotid ultrasound), progression of
aortic valve/root disease (echocardiography), and progres-
sion of coronary atherosclerosis (stress exercise tests).57,63
Additional details on aetiology, diagnosis, and treatment
of HoFH can be found in the Supplemental material sec-
tion “ADDITIONAL POINTS RELATED TO HOMO-
ZYGOUS FH.”
RECOMMENDATION
13. We recommend that a FH registry be implemented in
Canada to improve health outcomes in patients with
FH (Strong Recommendation, Moderate-Quality
Evidence).
Values and Preferences. FH registries in several Eu-
ropean countries have shown improvements in health
services utilization and cardiovascular outcomes. A similar
effort should be supported in Canada.
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Because of teratogenicity, women with FH who are plan-
ning pregnancy must interrupt statin therapy at least 1 month
before stopping contraception, and remain without therapy
until breastfeeding is completed. Adolescent and adult women
with HeFH of childbearing potential should receive counsel-
ling on contraception and pregnancy. For couples planning a
pregnancy in which one member has FH, the partner’s lipid
proﬁle should be screened before conception to exclude
coincident FH and the possibility of a child with HoFH;
when both parents have HeFH, prenatal counselling might be
sought. Barrier methods, intrauterine devices, tubal ligation,
or partner vasectomy are preferred because in theory these
have no effect on blood lipid levels and cardiovascular disease
risk. However, oral contraceptives are the usual default
method, for various reasons including convenience. No study
has examined cardiovascular disease risk in women with FH
who use oral contraceptives. If pregnancy occurs during statin
therapy, it must be stopped immediately and an obstetrician
consulted for early fetal evaluation, although the risk of fetal
complications is low.66 Cholestyramine, colestipol, or colese-
velam can be safely prescribed during pregnancy and breast-
feeding, but these reduce LDL-C by approximately 15% at
most and have tolerability issues. For HoFH subjects and FH
subjects with cardiovascular disease, LDL apheresis can
decrease LDL-C and prevent complications.67 For these
women, shared care and cardiovascular assessment are strongly
advised.RECOMMENDATION
12. We recommend that women with FH who are
considering pregnancy stop lipid-lowering therapy,
with the exception of bile acid-binding resins, at least
4 weeks before conception and until cessation of
breastfeeding (Strong Recommendation, Moderate-
Quality Evidence).
Values and Preferences. Statin therapy during preg-
nancy is contraindicated.Utility of an FH Registry
FH registries have been established in several European
countries, of which the Dutch registry is the most successful.
Using a cascade screening approach, 1500-2000 new FH cases
are diagnosed yearly in the Netherlands; about half of that
nation’s expected FH cases have been enrolled in the FH
registry. On average, 8 new cases are detected per family, and
treatment starts at a mean age of 37 years. The 98% partici-
pation rate reﬂects a positive attitude toward the screening
program.68 Results were impressive with early initiation of
treatment, with virtually complete avoidance of excess coro-
nary heart disease morbidity and mortality. Furthermore,
morbidity and mortality from other diseases (particularly
cancer) also signiﬁcantly decreased, attributed to the lifestyle
counselling.69
The United Kingdom National Institutes for Health and
Clinical Excellence (NICE) registry also uses cascade screeningwith genetic testing and LDL-C measurement to identify
affected relatives of FH index cases. This approach: (1)
reduced the average age at which the patients are diagnosed
and treated; (2) increased the proportion of patients with FH
who are receiving statin therapy, and who signiﬁcantly
decreased their lipid levels; (3) markedly reduced morbidity
and mortality from coronary heart disease when statin treat-
ment was initiated; (4) resulted in improved lipid levels in
children with FH; and (5) yielded cost-effective interventions,
with important economic beneﬁts for society.70Acknowledgements
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